secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2023-09-20T23:59:59+00:00
Accession:  0001193125-23-238295
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase provides pipeline updates after sharp stock decline; 201 Trial enrollment at 28 patients
--------------------------------------------------------------------------------

- Stock dropped dramatically over last 8 trading sessions; no identifiable cause for volatility.
- Risvodetinib 201 Trial: 28 of 120 patients enrolled/screening; one completed 12-week dosing; portal added 50 potential participants in Sept.
- Safety data for risvodetinib presented on 119 people at MDS Congress; no side effects of clinical significance.
- IkT-001Pro: FDA meeting request steps completed; bioequivalence study to 600 mg imatinib mesylate due early Q4 2023.
- Cash position sufficient to fund operations into Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523238295/0001193125-23-238295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523238295/d509876d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-238295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer